Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Gilead Sciences' Hepcludex (bulevirtide) wins first-ever FDA approval for chronic hepatitis D virus infection
Protein therapy, infectious disease, entry inhibitor, hepatitis D, bulevirtide - Read more

AstraZeneca, Daiichi Sankyo's Datroway (datopotamab deruxtecan) wins FDA approval for first-line TROP2-targeted triple-negative breast cancer
Antibody-drug conjugate, cancer, TROP2, triple-negative breast cancer, ADC - Read more

Pierre Fabre Laboratories secures CHMP backing for first-line BRAFTOVI regimen in BRAFV600E-mutant colorectal cancer
Small molecule, oncology, regulatory - Read more

AstraZeneca's camizestrant wins Europe CHMP backing despite FDA advisory committee rejection for breast cancer treatment
Small molecule, oral SERD, oncology - Read more

SK bioscience, VECOL partner on technology transfer to enable local varicella vaccine production in Colombia
Technology transfer, manufacturing agreement, vaccine, infectious disease - Read more

Gilead Sciences, Yuhan ink $139.8M API supply deal expanding long-standing manufacturing partnership
Manufacturing agreement, small molecule, supply chain, API sourcing - Read more

Roche, Medicines Patent Pool sign voluntary license enabling generic baloxavir production in 129 low- and middle-income countries
Licensing deal, infectious disease, small molecule, manufacturing agreement - Read more

Eli Lilly, Bristol Myers Squibb, Incyte strike AI partnerships to advance drug development workflows
AI/ML, Drug discovery, Research collaboration, Data analytics - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Kura Oncology's (darlifarnib) combo with Krazati shows up to 69% response rate in KRAS G12C-mutated solid tumors Ph1
Small molecule, cancer, KRAS inhibitor, non-small cell lung cancer, combination therapy, farnesyl transferase inhibitor - Read more

Eli Lilly's VERVE-102 (verve-102) shows 62% cholesterol reduction in Ph1b, targeting PCSK9 for hereditary high cholesterol
Gene therapy, cardiovascular, base editing, hypercholesterolemia, PCSK9, coronary artery disease - Read more

OSE Immunotherapeutics' OSE2101 plus Keytruda (pembrolizumab) shows Ph2 progression-free survival gain in recurrent ovarian cancer
Vaccine, cancer, neo-epitope vaccine, ovarian cancer, combination therapy, PD-1 inhibitor - Read more

Eli Lilly's (retatrutide) Ph3 triple hormone receptor agonist achieves bariatric surgery–like 28.3% weight loss in obesity
Small molecule, metabolic, triple agonist, obesity, GLP-1 receptor agonist - Read more - Read more

BioMarin's Voxzogo (vosoritide) hits Ph3 success in hypochondroplasia, rare skeletal disorder causing short stature
Small molecule, metabolic, rare skeletal disorder, hypochondroplasia, achondroplasia, CNP analog - Read more

Resolution Therapeutics' RTX001 macrophage therapy shows positive Ph1/2 EMERALD data in end-stage liver disease
Cell therapy, liver disease, macrophage therapy, liver cirrhosis, regenerative medicine - Read more

Niowave breaks ground on $75M Ac-225 radiopharmaceutical isotope plant in Michigan, targeting 2028 launch
Radiopharmaceutical, oncology, operational, major transaction - Read more

Eli Lilly to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8B to build infectious disease pipeline
Vaccine, infectious disease, strategic, major transaction - Read more

Curium Pharma allegedly makes ~$7B takeover offer for radiopharma company Lantheus Holdings
Radiopharmaceutical, oncology, major transaction, strategic - Read more

CVC Capital Partners and Groupe Bruxelles Lambert offer $12.4B to take Recordati private
Small molecule, rare disease, strategic, major transaction - Read more

Moderna's MFLUSIVA heads to FDA advisory committee review for influenza prevention in adults 50 and older
Vaccine, infectious disease, mRNA vaccine, influenza, elderly population - Read more

Kissei Pharmaceutical reverses Tavneos restriction, allowing new Japan patients with additional warnings (and after 20 deaths since 2022)
Small molecule, autoimmune, rare disease, safety - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

AbbVie cuts 85 jobs at Allergan's Irvine, California eye care unit effective July 20
Ophthalmology, operational, cost reduction, workforce restructuring - Read more

Astellas pins hopes on licensing deals, cost cuts ahead of Xtandi patent cliff
Small molecule, oncology, strategic, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here